Stockreport

Adagene Announces First Patients With Advanced Non-Small Cell Lung Cancer Dosed In Phase 1b/2 Clinical Trial Of ADG106 In Combination With Nivolumab In Singapore [TheStreet.com]

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF SAN DIEGO and SUZHOU, China, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced that the first patients have been dosed in a phase [Read more]